Using streptavidin-bound antibodies specific for both viral and cell membrane epitopes, we have reported previously that human cells may be infected by murine ecotropic retroviruses through an interaction with major histocompatibility complex class I and class II antigens, and thus have demonstrated that cell targeting by recombinant retroviruses is feasible. We report here that (i) growth factor or hormone receptors, such as those for epidermal growth factor (EGF) and insulin, can also mediate infection of human cells; (ii) a biotinylated cytokine or hormone can substitute for the anti-cell antibody in bispecific antibody complexes, thus extending the versatility of the method; (iii) although yields are low in our assay, infection efficiency clearly appears to depend upon the biochemical composition of molecular bridges because bi-functional antibody complexes are more efficient than cytokineantibody complexes in the case of the EGF receptor. Finally, our study indicates that different cell membrane molecules are not equally efficient in allowing infection of human cells because targeting of the transferrin, high density lipoprotein and galactose receptors, as well as that of various membrane glycoconjugates, by murine ecotropic retroviruses did not lead to the establishment of a proviral state.
Murine leukaemia-derived recombinant retroviruses (for reviews see Varmus, 1988; Temin, 1990) are commonly used for stable gene transfer in numerous experiments for fundamental purposes, and provide hope for gene therapy of human genetic deficiencies, cancer and AIDS (for reviews see Friedman, 1989; Temin, 1990) . Among the main limitations of this technology are the broad range of cell types infected by murine retroviruses, precluding their concentration in defined cells, and the resistance or semi-resistance of certain cell types to in vivo or in vitro infection. These two points have not yet received much attention. Nevertheless, in addition to improving gene therapy protocols by allowing better in vivo or ex vivo infection of cells of therapeutic interest, overcoming these limitations would have numerous in vivo and in vitro applications, such as immortalization of under-represented cell types from complex mixtures like biopsies, and targeted tumorigenesis, reconstitution of certain human pathologies or induction of developmental abnormalities in the animal.
Entry of retroviruses into host cells is mediated by specific cell surface receptors that bind the env geneencoded envelope glycoprotein (for a review see Dickson et al., 1984) . Accordingly, cell targeting can be defined as infection through virus interaction with cell surface molecules other than the natural receptor. In the case of Moloney murine leukaemia virus, the env glycoprotein is synthesized as a precursor (gp90) which undergoes proteolysis to produce two proteins associated by a disulphide bond: the p l5(E) transmembrane protein, responsible for the attachment of the complex to the virus, and the gp70 glycoprotein, responsible for the interaction with the receptor (Dickson et al., 1984) . Murine retroviruses can be divided into different classes according to their infection spectrum, the most widely used categories for gene transfer being the ecotropic viruses, which are able to infect murine cells only, and the amphotropic ones, which are also able to infect cells from other species including man. These differences are a direct consequence of structural variations of the gp70 protein which change the binding specificity (Teich, 1984) , suggesting that a first approach to targeting would involve engineering the env gene to confer new recognition specificity to the env protein by substituting cytokines, hormones or recombinant antibodies for the natural binding domain. Alternatively, using bispecific antibody complexes, made up of biotinylated immunoglobulins bridged with streptavidin, we have shown that biochemical linkers may also be used for infecting human cells with recombinant murine ecotropic retroviruses via major histocompatibility complex (MHC) class I and class II antigens (Roux et al., 1989a, b;  Neda et al. (1991) have shown that murine ecotropic retroviruses can infect human hepatic cells via the galactose receptor after chemical attachment of lactose onto the surface of purified virus particles. The experimental targeting system described here has been designed to allow direct comparison of both molecular adaptors and targeted receptor efficiencies. To this end, targeting was carried out at 0 °C to permit only one round of infection by abolishing cell membrane receptor turnover. The different components of the linkers were added to human cells according to the sequential protocol described in Roux et al. (1989a, b) . Murine ecotropic recombinant retroviruses carrying a bacterial neomycin resistance gene were then added and infected cells were selected for 12 to 15 days in the presence of G418 before counting of resistant clones. At least two independent experiments were carried out for each targeted receptor and different controls were included. (i) Only cells previously shown to be susceptible to infection by retroviruses via MHC class I molecules were used for testing new receptors (see Roux et al., 1989a, b) , thus ruling out the possibility that negative results could be due to an intrinsic resistance to infection; (ii) the binding of biotinylated antibodies or biotinylated proteins to the surface of paraformaldehyde-fixed cells was monitored visually in parallel experiments using rhodamine-labelled streptavidin according to Harlow & Lane (1988) ; (iii) when necessary, the binding of viruses to cells was tested using fluorescein isothiocyanate (FITC)-labelled anti-gp70 monoclonal antibodies (MAbs) (Harlow & Lane, 1988) ; (iv) biotinylated MAbs (273, 500 and 715) directed against the env glycoprotein (Chesebro et al., 1981 (Chesebro et al., , 1983 Chesebro & Wehrly, 1985) have been tested previously for their ability to drive targeted infection via MHC class I antigens and were used as a positive control; (v) it was verified that omitting any one part of the molecular adaptor resulted in no infection.
In an attempt to develop an easy method to overcome the species barrier, we first tested the possibility of using multivalent lectins able to bind membrane glycoconjugates of both viruses and cells. For infection experiments, HeLa cells were used and the linking capability of pokeweed mitogen (PWM), peanut agglutinin (PNA), soybean agglutinin (SBA), wheatgerm agglutinin (WGA), Ulex europaeus agglutinin (UeA-F) and the B chain of ricin was tested (all lectins are from Sigma, except ricin B, a kind gift from Dr P. Casellas). Lectins were added to cells at concentrations determined to be non-inhibitory for cell growth (1 ~tg/ml) using a classical dose-response assay. The pZip neo LT retrovirus (5 × 10 4) (Jat et al., 1986) , assayed on NIH 3T3 fibroblasts (Williams et al., 1984) and purified by centrifugation through a sucrose cushion according to Legrain et al. (1988) to remove glycoproteins and glycolipids contained in virus-producing cell culture supernatants, was used for infection. In no case were G418-resistant clones detected although the binding of virus particles was checked by immunodetection on paraformaldehyde-fixed cells using FITC-labeUed antigp70 MAbs (Table 1) .
HeLa cells show no intrinsic resistance to retrovirus infection; they are sensitive to amphotropic viruses as well as to MHC class I and class II antigen-mediated infection (Roux et al., 1989b) . This indicates that tight binding of viruses to the cell membrane is not sufficient for ensuring successful infection. Therefore, to extend our initial observation that streptavidin-bound biotinylated antibodies could allow cell targeting, we tested two other cell membrane markers: the receptors for transferrin and epidermal growth factor (EGF). Infection was performed according to the sequential addition protocol described by Roux et al. (1989b) using 1 ~tg of each component of the bridge per 5 × 105 cells. Biotinylated anti-EGF receptor antibodies were from Oncoscience and those against the transferrin receptor were a kind gift from Dr B. Bayard. As in the case of lectins, no G418-resistant clone developed when transferrin receptor-mediated infection of 5 × l0 s HepG2 cells was tested using 5 x 104 viruses (Table 1) . Conversely, the EGF receptor allowed infection of epithelial A431 cells with an efficiency comparable to that of MHC class I antigens (Roux et al., 1989a) (Table 2 ; 104 viruses/5 x l0 s cells). This led us to test the possibility that biotinylated proteins could substitute for the biotinylated anti-cell antibody in the bispecific antibody complexes by substituting biotinylated EGF (Oncoscience) for the anti-EGF receptor antibody. Interestingly, G418-resistant clones did develop after 2 weeks in culture, although six-to 10-fold less efficiently (Table 2 ). To ensure that infection was actually mediated by the molecular adaptor, several controls were included in parallel experiments. (i) Each component of the bridge was omitted separately, (ii) cells were preincubated with non-biotinylated EGF (Oncoscience) before the addition of biotinylated EGF or alternatively with a non-biotinylated antibody inhibiting the binding of EGF to its receptor, and (iii) biotinylated EGF was preincubated for 10 min at room temperature with a 20-fold excess of inhibiting anti-EGF antibody (Oncoscience) before the addition of the other components of the linker. Under none of these conditions were G418-resistant clones obtained, thus confirming the specificity of the binding.
To determine whether this approach is more widely applicable, we tested the possibility of infecting HeLa cells via the insulin receptor and of infecting hepatoma HepG2 cells via the galactose receptor using biotinylated insulin (Sigma) and biotinylated asialofetuin (kind gift from Dr B. Bayard), respectively (5 × 104 viruses/5 x 105 cells in each case). Although infection of HepG2 cells was never observed, HeLa cells were infected but at very low efficiency.
Finally, we evaluated the potential of the high density lipoprotein (HDL) receptor to mediate infection of hepatic HepG2 cells using a shorter bridge. For this purpose, a bacterially produced Apo A1-Protein A fusion protein (Monaco et al., 1988) was utilized owing to its ability to recognize both the HDL receptor and the Fc moiety of Ig. The anti-env MAbs 273, 500 and 715 (Chesebro et al., 1981 (Chesebro et al., , 1983 Chesebro & Wehrly, 1985) were used in separate experiments to link the fusion protein to retrovirus particles (5 x 104 viruses/5 x l0 s cells). Again, no G418-resistant clones developed (Table  1) confirming that, although being a limiting step, virus binding to cells is not sufficient to ensure infection.
We report that insulin and EGF receptors can render human cells susceptible to infection by murine ecotropic retroviruses and that a biotinylated protein can substitute for the anti-cell receptor antibody in our initial molecular bridges, thus extending the versatility of the method. However, we also report that other cell membrane markers, such as membrane glycoconjugates and the transferrin, galactose and HDL receptors, are inefficient for driving infection of human cells, at least under our experimental conditions. Interestingly, Goud et al. (1988) have shown that the transferrin receptor does allow internalization of retroviruses into epithelial Hep2 cells, but not the establishment of the proviral state, an observation in keeping with that reported here with hepatic HepG2 cells. This clearly indicates that resis-tance to infection can occur at the intracellular level and not only at that of cell recognition. Whether the intracellular fate of this particular receptor in Hep2 or HepG2 cells or other limiting steps, such as provirus formation or integration, are involved has not yet been investigated.
The major drawback of the method presented here obviously resides in the relatively low infectious yield; in the most favourable situation only 1 to 2~ of input retrovirus, as assayed on NIH 3T3 cells in the presence of polybrene (Williams et aL, 1984) , leads to actual infection and expression of carried genes. Three reasonable explanations can be put forward. First, large biochemical linkers inhibit early steps of virus infection such as virus-cell membrane fusion. Second, to obtain a direct comparison of receptor and linker efficiencies, only one round of infection was allowed by maintaining cells at 0 °C during the time of the targeting experiment. Third, stocks of viruses, whether purified or not, do contain two abundant competitors for the targeted receptors. On the one hand, only a few of the physical particles contained in a virus suspension produce complete infection because the majority of virus capsids lack genomic RNA (Dickson et al., 1984) and only a fraction of those which do contain RNA are capable of proviral integration (J.-L. Darlix, personal communication). On the other hand, the gp70 moiety of the env glycoprotein is not tightly attached to pl5(E), and substantial amounts of it are consequently found free in virus stocks. Experiments are presently under way in our laboratory to determine whether modifying the linker addition protocol, using anti-pl5(E) antibodies or smaller bridges, or performing infection at 37°C, improve targeting efficiency. Remarkably, EGF receptor targeting experiments suggest that the biochemical composition of molecular adaptors determines the infection efficiency because substituting the biotinylated growth factor for the anti-cell antibody in bispecific antibody complexes diminishes the number of G418-resistant clones. This is apparently supported by two other lines of evidence. First, we have previously reported that using Staphylococcus aureus Protein A instead of streptavidin to bridge antibodies has a negative effect on infection efficiency (Roux et al., 1989a) . Second, Neda et al. (1991) recently reported that grafting lactose onto viruses allows efficient infection of human hepatic HepG2 cells via the galactose receptor, an observation that differs from that reported here. Nevertheless it is worth noting that the experiments described by Neda et al. (1991) differ from ours in two other important aspects. (i) They allowed infection to proceed for 5 days at 37 °C and (ii) their characterization system was based on a transient fl-galactosidase gene expression assay performed 5 days after infection. Under these conditions, it cannot be ruled out that basal levels of the very stable fl-galactosidase protein result from basal transcription levels from proviral replication intermediates that have not integrated into the host genome, as already documented in the case of human immunodeficiency virus (Stevenson et al., 1990) , simian immunodeficiency virus (Prakash et al., 1992) and spleen necrosis virus (Panganiban & Temin, 1983) .
In conclusion, we report that cell targeting efficiency depends on both the nature of the receptor and the composition of biochemical linkers. These observations imply that the development of efficient techniques will require both an extensive screening of cell surface markers, for which the molecular adaptor method may prove valuable, and an extensive survey of methods for coupling viruses to cells, which will include engineering of the env glycoprotein for efficient in vivo targeting.
